Sofiniclin (ABT 894) is an agonist of nAChR as a potential non-stimulatory study in attention deficit disorder.
in vitro
ABT 894 is more potent than ABT-089 at both receptor subtypes, with K i values of 1.9 nM for 125 I-α-conotoxinMII binding and of 1.3 nM for 125 I-epibatidine binding.
in vivo
ABT 894 (0.001 to 0.10 mg/kg, po) produces significant reductions in LIDs compared to vehicle monkey. It does not decrease LIDs in monkeys with severe nigrostriatal damage.
